

TOBOS ABOGADOS S.A.S.

Calle 151 No. 18A-34

Oficina 409 Bogotá D.C.

C.P. 110131166 - Colombia

NIT 900.367.556-3

Tel +57 1 812 3335

Cel +57 320 334 0887

Fax +57 1 812 3335

<http://www.tobos.com.co>tobos@tobos.com.co

Superintendencia de Industria y Comercio

Radicado: 03011545

Folios : 39

Dependencia: Patentes Fecha: 2019-11-07 15:43:16

Tipo aplicación: Complementos de

Doctora

María José Lamus Becerra

Directora de Nuevas Creaciones

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO -SIC-

E.

S.

D.

PM

Referencia: Solicitud de patente de invención No. 03011545

Solicitante: Bristol – Myers Squibb Company

Título del Invento: Polimorfos de un análogo de Eptilona


Complemento de Información
SOLICITUD DE TRANSFERENCIA DE SOLICITANTE

ANDREA TOBOS MATEUS, mayor de edad y vecina de Bogotá D.C., identificada según aparece al pie de mi firma, como apoderada de la sociedad R-Pharma US Operating, LLC., solicito:

1. Se realice la modificación del solicitante en el caso de la referencia, según el documento de traspaso de la sociedad Bristol – Myers Squibb Company a favor de mi apoderada, la sociedad R-Pharma US Operating, LLC. el cual adjunto al presente memorial con su respectiva traducción al español.
2. Se realice la modificación del apoderado, teniendo en cuenta el poder firmado por el solicitante cedido.

Para tal efecto, adjunto comprobante de pago por traspaso de solicitante.

Atentamente,



ANDREA TOBOS MATEUS

C.C. 52.223.325 de Bogotá

T.P. 148648

Superintendencia de Industria y Comercio



Radicado: 03011545

Folios : 39

Dependencia: 2020 Fecha: 2019-11-07 15:43:16

Tipo aplicación: Complemento de Información

WM



Espacio reservado para el adhesivo de radicación

DELEGATURA PROPIEDAD INDUSTRIAL
MODIFICACIONES Y/O CORRECCIONES A SOLICITUDES EN TRAMITE

1. TIPO DE SOLICITUD ☒ MODIFICACION ☐ CORRECCION

1.1 IDENTIFICACION DEL TRÁMITE

- ☒ Patente de Invención / PCT
- ☐ Patente de Modelo de utilidad / PCT
- ☐ Diseño Industrial
- ☐ Esquema de Trazado de Circuito

2. DATOS DEL SOLICITANTE ☐ PERSONA NATURAL ☒ PERSONA JURÍDICA

Nombre o Denominación / Nombre Social		
Bristol - Myers Squibb Company		
Nombre del Representante		
Tipo de Empresa: ☐ Micro ☐ Pequeña ☐ Mediana ☒ Otra		
Documento de Identificación: ☐ C.C. ☐ C.E. ☐ NIT ☐ NUPI ☒ Otro		Número Identificación:
Nacionalidad/ País de Constitución:		Dirección
Estados Unidos de América		Princeton New Jersey, Estados Unidos de América
Dirección electrónica	No. Fax	Número telefónico
tobos@tobos.com.co		571 805 1166

3. DATOS DEL APODERADO

Apellidos y Nombre	Documento de identificación	Tarjeta profesional
TOBOS MATEUS, Andrea	52.223.325	148648
Dirección del Representante		
Carrera 7 C No. 138 - 19 Oficina 901 Bogotá, D.C. Colombia		
Dirección electrónica	No. Fax	Número telefónico
tobos@tobos.com.co		571 8051166

Número de Radicación o Protocolo de poder general: Adjunto

4. MODIFICACION Y/O CORRECCIÓN SOLICITADA

(Código actuación SIC - 608)

- ☐ Capítulo descriptivo
- ☐ Capítulo reivindicatorio
- ☐ Modificación a los dibujos

5. MODIFICACION Y/O CORRECCIÓN SOLICITADA

(Código actuación SIC - 587)

- ☒ Cesión / cambio solicitante ☐ Cambio de nombre ☐ Cambio de domicilio
- ☐ Cambio de dirección ☐ Nombre inventor ☐ Momento publicación
- ☐ Otra : Especifique _____

Aparece: Bristol - Myers Squibb Company

Debe ser: R- Pharma US Operating, LLC

Nacionalidad/ País de Constitución:	Dirección del solicitante	
Estados Unidos de América	3120 Princeton Pike, Suite 301 Lawrence New Jersey 08648	
Dirección electrónica	No. Fax	Número telefónico
tobos@tobos.com.co		805 1166

6. ANEXOS

- ☒ Comprobante de pago de la tasa para la presentación de la solicitud(es)
- ☒ Documentos que contienen las modificaciones o correcciones.
- ☒ Poder, si fuere el caso con el que se acredita la representación.
- ☐ Copia de la solicitud con sus anexos en medio magnético.

No.

Fecha:


7. FIRMA (S)

Andrea TOBOS MATEUS

Nombre de la Firmante

52.223.325

C.C.:



Firma

148648

Tarjeta Profesional

CESIÓN DE PATENTES

Esta CESIÓN DE PATENTES (esta "cesión"), con fecha del 1 de julio de 2015 (la "Fecha Efectiva") (esta "Cesión"), es por y entre BRISTOL-MYERS SQUIBB COMPANY (en adelante denominado "Cedente"), una corporación de Delaware que tiene oficinas en 345 Park Avenue, New York, New York 10154, y R-PHARM US OPERATING LLC, una compañía de responsabilidad limitada de Delaware (en lo sucesivo, denominado "Cesionario"). BMS y el Cesionario pueden ser denominados aquí individualmente como una "Parte" y juntos como las "Partes".

CONSIDERANDO que Cedente y R-PHARM US, LLC ("Comprador") han acordado en ese definitivo Contrato de compra de activos, con fecha de 5 de mayo de 2015, y sus modificaciones ocasionales posteriores (el "Contrato de compra"), en virtud del cual, entre otras cosas, el Cedente por la presente cede al cesionario todo del derecho, título e interés del Cedente en y para las Patentes propiedad del Vendedor o de cualquier Afiliado del Vendedor (como se definió en el Contrato de Compra) establecido en la Sección 1.02 (a) (i) (A) (I) y la Sección 1.02 (a) (i) (A) (II) de las listas de Información del Vendedor al Contrato de Compra, incluyendo todas las Patentes identificadas en la presente Lista A (las "Patentes Cedidas"), y el Cesionario desea aceptar las Patentes Cedidas por el Cedente.

Los términos en mayúscula utilizados, pero no definidos aquí, tendrán el significado establecido en el Contrato de compra.

AHORA, POR LO TANTO, en consideración de las premisas y los acuerdos y convenios mutuos expuestos, las Partes acuerdan lo siguiente:

1. Cesión. El Cedente confirma por la presente que, con efecto a partir de la Fecha límite (como se definió en el Contrato de compra), por la presente cede, vende y transfiere al cesionario todo su derecho, título e interés en y para cada una de las Patentes Cedidas, incluidas todas las continuaciones, divisionales, reediciones, duplicados, renovaciones, certificados de protección complementaria correspondientes y extensiones de cualquiera Patentes cedidas, junto con todos los derechos legales y derechos consuetudinario asociados en cualquiera de los anteriores, incluyendo, sin limitación, el derecho a reivindicar prioridad para las Patentes Cedidas bajo el Convenio Internacional para la Protección de la Propiedad Industrial y bajo cualquier acuerdo internacional similar al que el cesionario quede sujeto, y todas las defensas que se relacionen o surjan de cualquiera de las anteriores, y todos los derechos de acción que surjan de lo anterior, incluidos, entre otros, todos los reclamos por daños en razón de infracción presente, pasada y futura u otra violación de lo anterior y todo presente, pasado y futuro derechos a demandar y cobrar daños o buscar medidas cautelares por cualquier infracción u otra violación, y todos los ingresos, regalías y cualquier otro pago ahora y en adelante causado y/o pagadero al Cedente con respecto al anterior, en cada caso, para ser retenido y disfrutado por el Cesionario para su propio uso y beneficio, y para sus sucesores y causahabientes, tal como lo hubiera tenido el Cedente si no se hubiera realizado esta cesión; siempre que, sin embargo, todo lo anterior no incluya ningún derecho, título e interés en o a cualquiera de la Propiedad Intelectual Excluida.

2. Registro; Más garantías. Sujeto a la Sección 8.08 del Contrato de Compra, entre las Partes, el cesionario será responsable, a su exclusivo costo y gasto, de todos los registros aplicables (y la preparación de dichos registros y otros instrumentos de transferencia o cesión aplicables) de la

cesión o transferencia de las Patentes Cedidas. El Cedente deberá cooperar, perfeccionar tales documentos, y hacer y efectuar dichos actos, a cargo y costo único del Cesionario, según sea razonablemente solicitado por el cesionario para ayudar al cesionario a efectuar cualquiera de dichos registros o transferencias, documentar y registrar la cesión al Cesionario dispuesta en este contrato. El Cedente, por la presente, le solicita al Comisionado de Patentes y Marcas en la Oficina de Patentes y Marcas de los Estados Unidos, y a las entidades o agencias correspondientes en cualquier país extranjero o autoridad multinacional aplicable, a registrar al cesionario como cesionario y propietario de las Patentes Cedidas y entregarlo al Cesionario, y a los abogados, agentes, sucesores o causahabientes del cesionario, todos los documentos oficiales y las comunicaciones que resulten garantizadas por esta Cesión.

3. Contrapartes. Esta Cesión se puede perfeccionar en una o más copias, todas las cuales se considerarán uno y el mismo contrato, y entrarán en vigencia cuando una o más de tales copias hayan sido firmadas por cada una de las Partes y entregadas a la otra Parte, lo que puede ser por facsímil, páginas escaneadas u otros medios electrónicos.

4. Conflicto. Esta Cesión está sujeta en todos los aspectos a los términos y condiciones del Contrato de compra, y nada en esta Cesión, expreso o implícito, está destinado a, o deberá ser, interpretado por, (i) crear cualquier obligación adicional, convenios, contratos, representaciones o garantías o alterar, corregir, modificar, rescindir, renunciar, reemplazar o de alguna manera afectar cualquiera de las obligaciones, convenios, contratos, representaciones o garantías del Vendedor en virtud de, o los términos del, Contrato de Compra, o (ii) ampliar o limitar los respectivos derechos, beneficios, responsabilidades y obligaciones del vendedor o comprador previstas en o bajo el Contrato de Compra. Si hay algún conflicto entre el Contrato de Compra y esta Cesión, cada uno de los Contratos de Compra y esta Cesión debe ser interpretado y considerado, de ser posible, para evitar o minimizar dicho conflicto, pero, en la medida de tal conflicto, el contrato de compra prevalecerá y regirá.

5. Ley aplicable. ESTA CESIÓN Y TODAS LAS RECLAMACIONES O CAUSAS DE ACCIÓN (SEAN LEGALES, CONTRACTUALES, EXTRA CONTRACTUALES O DE OTRO TENOR) QUE PUEDAN BASARSE, SURGIR DE O RELACIONARSE CON ESTA CESIÓN O LA NEGOCIACIÓN, EJECUCIÓN O EL DESARROLLO DE LA PRESENTE DEBERÁ REGIRSE E INTERPRETARSE DE ACUERDO CON LAS LEYES INTERNAS DEL ESTADO DE NUEVA YORK APLICABLES A LOS ACUERDOS HECHOS Y A SER REALIZADOS EN SU TOTALIDAD EN DICHO ESTADO, SIN CONSIDERAR LOS CONFLICTOS DE LOS PRINCIPIOS LEGALES DE TAL ESTADO.

6. Partes interesadas. Esta cesión de patente será vinculante y redundará en beneficio de las Partes del presente y sus respectivos sucesores y causahabientes.

* * * * *

[FIN DE PÁGINA]

[SIGUE LA PÁGINA DE FIRMAS]

En testimonio de lo cual, el Cedente ha perfeccionado esta cesión por medio de su funcionario debidamente autorizado en la fecha establecida adelante.

CEDENTE

BRISTOL-MYERS SQUIBB COMPANY

Por: Firmado Ilegible

Brian P. Heaphy

Director Ejecutivo, Fusiones y Adquisiciones

Fecha: 01 de julio de 2015

Estado de New York

Condado de New York

Este día 1ero de julio de 2015, apareció ante mí personalmente Brian P. Heaphy, conocido por mí personalmente (o quien lo probó con evidencia satisfactoria) como la persona cuyo nombre esta suscrito en el instrumento y reconoció que ha perfeccionado el mismo por su capacidad autorizada, y que por medio de esta firma en el instrumento la persona, o la entidad a nombre de quien actuó la persona, perfeccionó el instrumento

Notario Público

PETER JOSEPH CAMPISI, JR.

Notario Público, Estado de New York

No. 02CA6305160

Cualificado en el Condado de New York

Comisión Expira junio 2, 2018

EN TESTIMONIO DE LO CUAL, el Cesionario reconoce y acepta esta Cesión este día 30 de junio de 2015.

CESIONARIO

R-PHARM US OPERATING, LLC

Por: Firmado Ilegible

Nombre Demetios Kydonieus

Título Presidente

Estado de New Jersey
Condado de Mercer

Este día 30 de junio de 2015, apareció personalmente ante mi Demetrios Kydonieus conocido personalmente por mi (o quien lo probó con evidencia satisfactoria) como la persona cuyo nombre está suscrito en el instrumento y reconoció que ha perfeccionado el mismo por su capacidad autorizada, y que por medio de esta firma en el instrumento la persona, o la entidad a nombre de quien actuó la persona, perfeccionó el instrumento.

Notario Público
HELEN SUE MEHALIC
Notario Público de New Jersey
Mi comisión Expira 5/14/2017

(Página de firmas de la Cesión de Patentes Por R-PHARM US OPERATING, LLC)

LISTA A
Patentes Cedidas

Referencia No.	Estado	Solicitud No.	Fecha	No. de Otorgamiento	Fecha de Otorgamiento
Título					
POLIMEROS DE UN ANALOGO DE EPOTILONA					
LD2014-CO-PCT	Pendiente	03011545	08/01/2001		

ASSIGNMENT OF PATENTS

This ASSIGNMENT OF PATENTS (this "Assignment"), dated as of July 1, 2015 (the "Effective Date") (this "Assignment"), is by and between **BRISTOL-MYERS SQUIBB COMPANY** (hereinafter referred to as "Assignor"), a Delaware corporation having offices at 345 Park Avenue, New York, New York 10154, and **R-PHARM US OPERATING LLC**, a Delaware limited liability company (hereinafter referred to as "Assignee"). BMS and Assignee may be referred to herein individually as a "Party" and together as the "Parties".

WHEREAS, Assignor and **R-PHARM US, LLC** ("Purchaser") have entered into that certain Asset Purchase Agreement, dated as of May 5, 2015, as amended from time to time thereafter (the "Purchase Agreement"), pursuant to which, among other things, Assignor hereby assigns to Assignee all of Assignor's right, title and interest in and to the Patents owned by Seller or any Selling Affiliate (as defined in the Purchase Agreement) set forth in Section 1.02(a)(i)(A)(I) and Section 1.02(a)(i)(A)(II) of the Seller Disclosure Schedules to the Purchase Agreement, including all Patents identified in Schedule A hereto (the "Assigned Patents"), and Assignee desires to accept the Assigned Patents from Assignor. Capitalized terms used but not defined herein shall have the meaning set forth in the Purchase Agreement.

NOW THEREFORE, in consideration of the premises and the mutual agreements and covenants hereinafter set forth, the Parties hereto agree as follows:

1. Assignment. Assignor does hereby confirm that, with effect from the Closing Date (as defined in the Purchase Agreement), it hereby assigns, sells and transfers to Assignee its entire right, title and interest in and to each of the Assigned Patents, including all continuations, divisionals, reissues, counterparts, renewals, corresponding supplementary protection certificates and extensions of any Assigned Patents, together with all associated statutory and common law rights in any of the foregoing, including, without limitation, the right to claim priority for the Assigned Patents under the International Convention for the Protection of Industrial Property and under any similar international arrangement to which Assignee becomes subject, and all defenses relating to or arising from any of the foregoing, and all rights of action arising from the foregoing, including, without limitation, all claims for damages by reason of present, past and future infringement or other violation of the foregoing and all present, past and future rights to sue and collect damages or seek injunctive relief for any such infringement or other violation, and all income, royalties and any other payments now and hereafter due and/or payable to Assignor in respect of the foregoing, in each case, to be held and enjoyed by Assignee for its own use and benefit and for its successors and assigns as the same would have been held by Assignor had this assignment not been made; provided, however, all of the foregoing shall not include any right, title and interest in or to any of the Excluded Intellectual Property.

2. Recordation; Further Assurances. Subject to Section 8.08 of the Purchase Agreement, as between the Parties, Assignee shall be responsible, at its sole cost and expense, for all applicable recordations (and preparation of such recordations and other applicable instruments of transfer or assignment) of the assignment or transfer of the Assigned Patents. Assignor shall cooperate, execute such documents, and do and perform such acts, at Assignee's sole cost and expense, as may be reasonably requested by Assignee to assist Assignee in any such recordings or transfers to give effect to, document and record the assignment to Assignee under this Assignment. Assignor hereby requests the Commissioner of Patents and Trademarks in the United States Patent and Trademark Office, and the corresponding entities or agencies in any applicable foreign countries or multinational authorities, to record Assignee as the assignee and owner of the Assigned Patents and to deliver to Assignee, and to

Assignee’s attorneys, agents, successors or assigns, all official documents and communications as may be warranted by this Assignment.

3. Counterparts. This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when one or more such counterparts have been signed by each of the Parties and delivered to the other Party which may be by facsimile, scanned pages or other electronic means.

4. Conflict. This Assignment is subject in all respects to the terms and conditions of the Purchase Agreement, and nothing in this Assignment, express or implied, is intended to, or shall be construed to, (i) create any additional obligations, covenants, agreements, representations or warranties or alter, amend, modify, rescind, waive, supersede or in any way affect any of the obligations, covenants, agreements, representations or warranties of Seller under, or the terms of, the Purchase Agreement, or (ii) expand upon or limit the respective rights, benefits, responsibilities and obligations of Seller or Purchaser provided in or under the Purchase Agreement. If there is any conflict between the Purchase Agreement and this Assignment, each of the Purchase Agreement and this Assignment is to be interpreted and construed, if possible, so as to avoid or minimize such conflict, but, to the extent of such conflict, the Purchase Agreement shall prevail and control.

5. Governing Law. THIS ASSIGNMENT AND ALL CLAIMS OR CAUSES OF ACTION (WHETHER AT LAW, IN CONTRACT, IN TORT OR OTHERWISE) THAT MAY BE BASED UPON, ARISE OUT OF OR RELATE TO THIS ASSIGNMENT OR THE NEGOTIATION, EXECUTION OR PERFORMANCE HEREOF SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES OF SUCH STATE.

6. Parties in Interest. This Patent Assignment shall be binding upon and inure to the benefit of the Parties hereto and their respective successors and assigns.

* * * * *

[END OF PAGE]
[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Assignor has caused this Assignment to be executed by its duly authorized officer on the date set forth below.

ASSIGNOR

Bristol-Myers Squibb Company

By: Brian P. Heaphy
Brian P. Heaphy
Executive Director, Mergers & Acquisitions

Date: July 1, 2015

State of New York)

)ss:

County of New York)

On this 1st day of July, 2015, before me personally appeared Brian P. Heaphy, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Peter Joseph Campisi, Jr.
Notary Public

PETER JOSEPH CAMPISI, JR.
Notary Public, State of New York
No. 02CA6305180
Qualified in New York County
Commission Expires June 2, 2018

IN WITNESS WHEREOF, the Assignee acknowledges and accepts this Assignment this 30 day of June 2015.

ASSIGNEE
R-PHARM US OPERATING, LLC

By: 
Name Demetrios Kydonieus
Title President

State of New Jersey)
)ss:
County of Monmouth)

On this 30th day of June, 2015, before me personally appeared Demetrios Kydonieus personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that s/he executed the same in his/her authorized capacity, and that by his/her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.


Notary Public

HELEN SUE MEHALIK
Notary Public of New Jersey
My Commission Expires 5/14/2017

SCHEDULE A**Assigned Patents**

Docket No.	Status	Application No.	Application Date	Grant No.	Grant Date
Title					
PROCESS AND FORMULATION CONTAINING EPOTHILONES AND ANALOGS THEREOF					
10103-US-CNT	Granted	12/557822	09/11/2009	8871227	10/28/2014
Title					
METHODS FOR DETERMINING SENSITIVITY TO MICROTUBULE-STABILIZING AGENTS COMPRISING IXABEPILONE BY MEASURING THE LEVEL OF ESTROGEN RECEPTOR 1					
10338-US-CNT[1]	Granted	11/906248	10/01/2007	7932031	04/26/2011
Title					
PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS					
LD0189-SK-PCD	Pending	2012-5013	05/11/2012		
LD0189-SK-PCT	Pending	PV2003-1997	01/16/2002		
LD0189-US-CNT[2]	Granted	12/264375	11/04/2008	8632788	01/21/2014
LD0189-US-CNT[4]	Pending	14/686005	04/14/2015		
LD0189-US-NP	Granted	10/051727	01/17/2002	7022330	04/04/2006
Title					
POLYMORPHS OF AN EPOTHILONE ANALOG					
LD0214-AL-PCT	Granted	AL/P/03/00612	08/01/2001	2711	01/27/2009
LD0214-AR-NP	Pending	P010103901	08/15/2001		
LD0214-AT-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007
LD0214-AU-PCT	Granted	2001/281082	08/01/2001	2001281082	04/19/2007
LD0214-BE-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007
LD0214-BG-PCT	Granted	107467	08/01/2001	66132	04/19/2011
LD0214-BR-PCT	Pending	PI0113234.2	08/01/2001		
LD0214-CA-PCT	Granted	2418109	08/01/2001	2418109	09/27/2011
LD0214-CH-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007
LD0214-CL-NP	Granted	1941/01	08/10/2001	49924	05/05/2014
LD0214-CN-PCT	Granted	01817064.1	08/01/2001	01817064.1	08/16/2006
LD0214-CO-PCT	Pending	03011545	08/01/2001		
LD0214-CY-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007
LD0214-CZ-PCT	Pending	PV2003/418	08/01/2001		
LD0214-DE-EPT	Granted	01959536.2	08/01/2001	60129334.7	07/11/2007
LD0214-DK-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007
LD0214-EE-PCT	Granted	P200300063	08/01/2001	05273	02/15/2010
LD0214-EP-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007
LD0214-ES-EPT	Granted	01959536.2	08/01/2001	2288518	07/11/2007
LD0214-FI-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007
LD0214-FR-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007
LD0214-GB-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007
LD0214-GE-PCT	Granted	4156/01	08/01/2001	3495	04/25/2005
LD0214-GR-EPT	Granted	01959536.2	08/01/2001	3063404	07/11/2007
LD0214-HK-FPR	Granted	03104338.0	08/01/2001	1052010	01/25/2008
LD0214-HR-PCT	Pending	P20030190A	08/01/2001		
LD0214-HU-PCT	Granted	P0300826	08/01/2001	229314	10/01/2013
LD0214-IE-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007

Docket No.	Status	Application No.	Application Date	Grant No.	Grant Date
LD0214-IL-PCT	Granted	153993	08/01/2001	153993	10/21/2009
LD0214-IN-MBA	Granted	89/MUMNP/2003	08/01/2001	223589	09/30/2008
LD0214-IS-PCT	Pending	6714	08/01/2001		
LD0214-IT-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007
LD0214-JP-PCT	Granted	2002/519462	08/01/2001	5046467	07/27/2012
LD0214-KR-PCT	Granted	10-2003-7002256	08/01/2001	810342	02/27/2008
LD0214-LT-PCT	Granted	2003-017	08/01/2001	5138	06/25/2004
LD0214-LU-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007
LD0214-LV-PCT	Granted	P-03-28	08/01/2001	13032	12/20/2003
LD0214-MC-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007
LD0214-MK-PCT	Granted	P-20030059	08/01/2001	901170	12/11/2005
LD0214-MX-PCT	Granted	PA/A/03/001431	08/01/2001	233513	01/06/2006
LD0214-NL-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007
LD0214-NO-PCT	Granted	2003/0707	08/01/2001	328500	03/01/2010
LD0214-NZ-PCT	Granted	523722	08/01/2001	523722	08/11/2005
LD0214-PL-PCT	Granted	P-365610	08/01/2001	205628	12/29/2009
LD0214-PT-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007
LD0214-RO-PCT	Granted	2003-00114	08/01/2001	123296	08/31/2010
LD0214-RU-PCT	Granted	2003106431	08/01/2001	2272039	03/20/2006
LD0214-SE-EPT	Granted	01959536.2	08/01/2001	1309597	07/11/2007
LD0214-SI-PCT	Granted	P-200120055	08/01/2001	21100	07/02/2003
LD0214-SK-PCT	Granted	2003-134	08/01/2001	287876	12/12/2011
LD0214-TR-EPT	Granted	01959536.2	08/01/2001	TR200706825	07/11/2007
LD0214-TW-NP	Granted	90119585	08/10/2001	NI-320040	02/01/2010
LD0214-US-CNT[1]	Granted	10/773819	02/06/2004	6982276	01/03/2006
LD0214-US-CNT[2]	Granted	11/271456	11/10/2005	7153879	12/26/2006
LD0214-US-NP	Reissue	09/925112	08/09/2001	6689802	02/10/2004
LD0214-US-REI	Granted	11/076589	03/09/2005	RE39251	08/29/2006
LD0214-VE-NP	Pending	1747-2001	08/14/2001		
LD0214-ZA-PCT	Granted	2003/0522	08/01/2001	03/0522	06/30/2004
Title					
TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES					
LD0260-US-NP	Reissue	10/072123	02/08/2002	6686380	02/03/2004
LD0260-US-REI	Granted	11/346579	02/02/2006	RE41393	06/22/2010
Title					
COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES					
LD0268-AU-PCT	Granted	2002248542	03/05/2002	2002248542	05/03/2007
LD0268-BG-PCT	Granted	108137	03/05/2002	66289	08/28/2003
LD0268-BR-PCT	Pending	PI0207961.5	03/05/2002		
LD0268-CZ-PCT	Pending	PV2003-2376	03/05/2002		
LD0268-DE-EPT	Granted	02717548.8	03/05/2002	1383490	04/25/2012
LD0268-EE-PCT	Granted	P200300440	03/05/2002	5417	06/15/2011
LD0268-EP-EPT	Granted	02717548.8	03/05/2002	1383490	04/25/2012
LD0268-ES-EPT	Granted	02717548.8	03/05/2002	1383490	04/25/2012
LD0268-FR-EPT	Granted	02717548.8	03/05/2002	1383490	04/25/2012
LD0268-GB-EPT	Granted	02717548.8	03/05/2002	1383490	04/25/2012
LD0268-HK-FPR	Granted	04103790.2	03/05/2002	1060843	04/19/2013
LD0268-HR-PCT	Granted	P20030831A	03/05/2002	P20030831	07/24/2012

Docket No.	Status	Application No.	Application Date	Grant No.	Grant Date
LD0268-HU-PCT	Pending	P0400203	03/05/2002		
LD0268-IL-PCT	Granted	157443	03/05/2002	157443	03/30/2012
LD0268-IS-PCT	Granted	6950	03/05/2002	2882	05/15/2014
LD0268-IT-EPT	Granted	02717548.8	03/05/2002	1383490	04/25/2012
LD0268-MX-PCT	Granted	PA/A/03/008135	03/05/2002	257954	06/16/2008
LD0268-NO-PCT	Granted	20034056	03/05/2002	333972	11/04/2013
LD0268-RU-PCT	Granted	2003130377	03/05/2002	2321400	04/10/2008
LD0268-SG-PCT	Granted	200305431-9	03/05/2002	99594	01/27/2006
LD0268-SK-PCT	Pending	2003-1108	03/05/2002		
LD0268-TH-NP	Pending	072273	03/12/2002		
LD0268-TW-NP	Granted	91104423	03/08/2002	NI-330530	09/21/2010
LD0268-US-DIV[1]	Granted	10/850072	05/20/2004	8569347	10/29/2013
LD0268-US-DIV[3]	Granted	12/508100	07/23/2009	8598215	12/03/2013
LD0268-US-NP	Granted	10/091061	03/05/2002	7312237	12/25/2007
LD0268-ZA-PCT	Granted	2003/7123	03/05/2002	03/7123	02/23/2005
Title					
PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND METHODS FOR ORAL ADMINISTRATION OF EPOTHILONES					
LD0272-US-NP	Reissue	10/057390	01/25/2002	6576651	06/10/2003
LD0272-US-REI	Granted	11/149501	06/09/2005	RE40387	06/17/2008
Title					
METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B ¹					
LD0283-AU-PCT	Granted	2003275068	09/22/2003	2003275068	01/07/2010
LD0283-BR-PCT	Pending	PI0314133.0	09/22/2003		
LD0283-CA-PCD	Granted	2695720	03/08/2010	2695720	04/02/2013
LD0283-CA-PCT	Granted	2499600	09/22/2003	2499600	08/21/2012
LD0283-CN-DIV[1]	Granted	200710089045.0	11/10/2006	200710089045.0	08/10/2011
LD0283-CN-PCT	Granted	03822662.6	09/22/2003	03822662.6	07/06/2011
LD0283-CO-PCT	Granted	05026479	09/22/2003	2043	04/17/2012
LD0283-DE-ETD	Granted	10181150.3	09/28/2010	60345171.3	10/23/2013
LD0283-DE-ETD[2]	Granted	10181230.3	09/28/2010	60343299.9	02/13/2013
LD0283-EP-ETD	Granted	10181150.3	09/28/2010	2280014	10/23/2013
LD0283-EP-ETD[2]	Granted	10181230.3	09/28/2010	2287168	02/13/2013
LD0283-ES-ETD	Granted	10181150.3	09/28/2010	2280014	10/23/2013
LD0283-ES-ETD[2]	Granted	10181230.3	09/28/2010	2287168	02/13/2013
LD0283-FR-ETD	Granted	10181150.3	09/28/2010	2280014	10/23/2013
LD0283-FR-ETD[2]	Granted	10181230.3	09/28/2010	2287168	02/13/2013
LD0283-GB-ETD	Granted	10181150.3	09/28/2010	2280014	10/23/2013
LD0283-GB-ETD[2]	Granted	10181230.3	09/28/2010	2287168	02/13/2013
LD0283-HK-DIV[1]	Granted	08103225.3	03/19/2008	1113387	06/08/2012
LD0283-IL-PCD	Granted	222455	10/28/2012	222455	01/31/2015
LD0283-IL-PCT	Granted	166868	09/22/2003	166868	12/31/2012
LD0283-IT-ETD	Granted	10181150.3	09/28/2010	2280014	10/23/2013
LD0283-IT-ETD[2]	Granted	10181230.3	09/28/2010	2287168	02/13/2013
LD0283-JP-PCD	Granted	2009-243115	10/22/2009	5193983	02/08/2013

Docket No.	Status	Application No.	Application Date	Grant No.	Grant Date
LD0283-JP-PCT	Granted	2004-538301	09/22/2003	4523843	06/04/2010
LD0283-KR-PCD	Granted	10-2012-7014263	06/01/2012	1406635	06/03/2014
LD0283-MX-PCT	Granted	PA/A/05/003006	09/22/2003	254852	02/18/2008
LD0283-NO-PCT	Granted	20050929	09/22/2003	334167	12/23/2013
LD0283-RU-PCT	Granted	2005112443	09/22/2003	2368661	09/27/2009
LD0283-TW-NP	Granted	92126105	09/22/2003	NI291464	12/21/2007
LD0283-US-DIV[1]	Granted	10/805724	03/22/2004	7241899	07/10/2007
LD0283-US-DIV[2]	Granted	11/669268	01/31/2007	7767432	08/03/2010
LD0283-US-NP	Reissue	10/668032	09/22/2003	7172884	02/06/2007
LD0283-US-REI	Granted	12/462816	08/06/2009	RE42191	03/01/2011
LD0283-ZA-PCT	Granted	2005/01680	09/22/2003	05/01680	05/31/2006
Title					
METHODS OF ADMINISTERING EPOTHILONE ANALOGS FOR THE TREATMENT OF CANCER					
LD0284-AR-DIV	Pending	P140103915	10/17/2014		
LD0284-AR-NP	Pending	P020100287	01/25/2002		
LD0284-AT-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-AU-PCT	Granted	2002245296	01/22/2002	2002245296	04/05/2007
LD0284-BE-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-BG-PCT	Pending	108112	01/22/2002		
LD0284-BR-PCT	Pending	PI0206509.6	01/22/2002		
LD0284-CA-PCD	Granted	2681962	10/08/2009	2681962	06/12/2012
LD0284-CA-PCT	Granted	2434526	01/22/2002	2434526	11/01/2011
LD0284-CH-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-CL-NP	Pending	0135/02	01/24/2002		
LD0284-CN-DIV[1]	Granted	200710142237.3	08/22/2007	200710142237.3	06/20/2012
LD0284-CN-PCT	Granted	02804090.2	01/22/2002	02804090.2	10/10/2007
LD0284-CO-PCT	Pending	03062158	01/22/2002		
LD0284-CY-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-CZ-PCT	Pending	PV2021-03	01/22/2002		
LD0284-DE-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-DK-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-EE-PCT	Granted	0320/03PC	01/22/2002	05301	06/15/2010
LD0284-EG-MBA	Pending	85/2002	01/23/2002		
LD0284-EP-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-EP-ETD	Pending	08152923.2	03/18/2008		
LD0284-ES-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-FI-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-FR-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-GB-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-GR-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-HK-DIV[1]	Granted	08106497.7	06/12/2008	1116339	03/15/2013
LD0284-HK-FPR	Granted	04108838.5	11/10/2004	1065946	08/01/2008
LD0284-HR-PCT	Pending	P20030677A	01/22/2002		
LD0284-HU-PCD	Pending	P1300401	07/25/2013		
LD0284-HU-PCT	Granted	P0302726	01/22/2002	229349	10/09/2013
LD0284-IE-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-IL-PCT	Granted	156578	01/22/2002	156578	12/01/2012
LD0284-IN-DIV[1]	Pending	2059/MUMNP/07	12/04/2007		
LD0284-IN-MBA	Granted	640/MUMNP/2003	01/22/2002	224075	09/29/2008
LD0284-IS-PCT	Granted	6891	01/22/2002	2865	02/15/2014

Docket No.	Status	Application No.	Application Date	Grant No.	Grant Date
LD0284-IT-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-JP-PCT	Granted	2002-559034	01/22/2002	4633331	11/26/2010
LD0284-KR-PCT	Granted	10-2003-7009825	01/22/2002	851719	08/05/2008
LD0284-LT-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-LU-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-LV-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-MC-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-MK-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-MX-PCT	Granted	PA/A/03/006412	01/22/2002	258388	07/02/2008
LD0284-NL-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-NO-PCD	Pending	20130070	02/04/2013		
LD0284-NO-PCT	Granted	20033341	01/22/2002	335119	09/22/2014
LD0284-NZ-PCT	Granted	526870	01/22/2002	526870	03/09/2006
LD0284-PE-NP	Granted	000062-2002-OIN	01/25/2002	4887	02/21/2008
LD0284-PL-PCT	Granted	P-373727	01/22/2002	207720	09/21/2010
LD0284-PT-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-RO-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-RU-PCT	Granted	2003126170	01/22/2002	2292202	01/27/2007
LD0284-SE-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-SG-PCT	Granted	200303981-5	01/22/2002	98615	08/31/2005
LD0284-SI-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-SK-PCD	Pending	5013-2012	05/11/2012		
LD0284-SK-PCT	Granted	PP2003-856	01/22/2002	288098	05/20/2013
LD0284-TH-NP	Pending	071368	01/24/2002		
LD0284-TR-EPT	Granted	02713446.9	01/22/2002	1353668	03/19/2008
LD0284-TW-NP	Granted	91101089	01/23/2002	NI-342211	05/21/2011
LD0284-US-NP	Granted	10/055653	01/23/2002	6670384	12/30/2003
LD0284-US-REX	Granted	90/007605	06/27/2005	6670384	01/23/2007
LD0284-UY-NP	Pending	27.137	01/25/2002		
LD0284-VE-NP	Pending	132-2002	01/25/2002		
LD0284-ZA-PCT	Granted	2003/5126	01/22/2002	03/5126	12/29/2004
Title					
EPOTHILONE DERIVATIVES ²					
LD125-AR-NP	Granted	P980103322	07/08/1998	AR013358B1	05/30/2006
LD125-AT-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-AU-PCT	Granted	79720/98	06/16/1998	731497	07/12/2001
LD125-BE-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-BG-PCT	Granted	104068	06/16/1998	64952	06/20/2006
LD125-BR-PCD	Pending	PI9816352.3	12/03/2010		
LD125-BR-PCT	Pending	PI9810555.8	06/16/1998		
LD125-CA-PCT	Granted	2296012	06/16/1998	2296012	10/21/2008
LD125-CH-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-CH-SPC	Granted	C01019389/01	05/14/2009	C01019389/01	09/30/2011
LD125-CL-NP	Granted	1519/98	06/26/1998	46906	10/01/2010
LD125-CN-PCT	Granted	98806906.7	06/16/1998	98806906.7	04/30/2008
LD125-CO-NP	Pending	98038387	07/07/1998		
LD125-CY-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005

Docket No.	Status	Application No.	Application Date	Grant No.	Grant Date
LD125-CZ-PCT	Granted	PV58-2000	06/16/1998	297904	03/15/2007
LD125-DE-EPD	Granted	04021059.3	09/03/2004	1493738	03/25/2009
LD125-DE-EPT	Granted	98930300.3	06/16/1998	69832294.0	11/09/2005
LD125-DK-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-EC-NP	Granted	SP-98-2576	07/03/1998	PI-07-1893	10/31/2007
LD125-EE-PCT	Granted	P200000013	06/16/1998	04566	12/12/2005
LD125-EG-MBA	Granted	792/98	07/07/1998	24464	07/16/2009
LD125-EP-EPD	Granted	04021059.3	09/03/2004	1493738	03/25/2009
LD125-EP-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-ES-EPD	Granted	04021059.3	09/03/2004	1493738	03/25/2009
LD125-ES-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-FI-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-FR-EPD	Granted	04021059.3	09/03/2004	1493738	03/25/2009
LD125-FR-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-GB-EPD	Granted	04021059.3	09/03/2004	1493738	03/25/2009
LD125-GB-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-GE-PCT	Granted	1998003815	06/16/1998	P2897	02/25/2003
LD125-GR-EPT	Granted	98930300.3	06/16/1998	3056454	11/09/2005
LD125-HK-FPR	Granted	00106086.2	02/08/2006	1026905	03/31/2006
LD125-HK-FPR[1]	Granted	01102362.5	04/02/2001	1031731	04/24/2009
LD125-HU-PCT	Granted	P0103111	06/16/1998	227444	11/24/2011
LD125-IE-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-IL-PCT	Granted	133613	06/16/1998	133613	02/21/2006
LD125-IT-EPD	Granted	04021059.3	09/03/2004	1493738	03/25/2009
LD125-IT-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-JP-DIV[1]	Granted	2007-156260	06/13/2007	4885067	12/16/2011
LD125-JP-PCT	Granted	508673/1999	06/16/1998	4090514	03/07/2008
LD125-KR-EXT	Granted	10-2008-0086826	09/03/2008	569041	12/01/2008
LD125-KR-PCT	Granted	10-2000-7000120	06/16/1998	569041	04/03/2006
LD125-LT-PCT	Granted	99-153	06/16/1998	4743	12/27/2000
LD125-LU-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-LV-PCT	Granted	P-0017	06/16/1998	12569	04/20/2001
LD125-MC-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-MX-PCT	Granted	9911452	06/16/1998	238918	07/25/2006
LD125-NL-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-NO-PCT	Granted	20000076	06/16/1998	322494	10/16/2006
LD125-NZ-PCT	Granted	501198	06/16/1998	501198	01/10/2002
LD125-PH-NP	Granted	1-1998-01383	06/06/1998	1-1998-01383	05/16/2006
LD125-PL-PCT	Granted	P.338003	06/16/1998	197404	09/11/2007
LD125-PT-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-RO-PCT	Granted	99-01332	06/16/1998	120340	10/27/2005
LD125-RU-EXT	Pending	2213741	03/15/2012		
LD125-RU-PCT	Granted	2000102893	06/16/1998	2213741	10/10/2003
LD125-SE-EPT	Granted	98930300.3	06/16/1998	1019389	11/09/2005
LD125-SG-PCT	Granted	9905820-8	06/16/1998	69499	03/31/2005
LD125-SK-PCT	Granted	PV1817-99	06/16/1998	286592	11/27/2008
LD125-TH-NP	Pending	044770	07/06/1998		
LD125-TR-PCT	Granted	00/65	06/16/1998	TR200000065B	02/21/2005
LD125-TW-EXT	Granted	87110722	07/27/2009	I-191434	11/12/2012
LD125-TW-NP	Granted	87110722	07/02/1998	NI-191434	03/23/2004
LD125-UY-NP	Granted	25.082	07/06/1998	14.027	04/15/2002

Docket No.	Status	Application No.	Application Date	Grant No.	Grant Date
LD125-VE-NP	Pending	1502/1998	07/08/1998		
LD125-ZA-NP	Granted	98/5938	07/06/1998	98/5938	03/29/2000
LD125B-US-CNT[1]	Granted	10/405886	04/03/2003	7125899	10/24/2006
LD125B-US-CNT[2]	Reissue	11/512623	08/30/2006	7241755	07/10/2007
LD125B-US-CNT[3]	Granted	11/763636	06/15/2007	8536327	09/17/2013
LD125B-US-CNT[4]	Granted	13/966613	08/14/2013	8921542	12/30/2014
LD125B-US-CNT[5]	Pending	14/553081	11/25/2014		
LD125B-US-NP	Reissue	09/084542	05/26/1998	6605599	08/12/2003
LD125B-US-REI	Granted	12/539492	08/11/2009	RE41911	11/02/2010
LD125B-US-REI[2]	Granted	12/539496	08/11/2009	RE41895	10/26/2010
LD125B-US-REI[3]	Granted	12/539498	08/11/2009	RE41893	10/26/2010
LD125B-US-REI[4]	Granted	12/882769	09/15/2010	RE43003	12/06/2011
Title					
PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS					
LD140A-US-NP	Granted	09/170582	10/13/1998	6365749	04/02/2002
LD140B-AU-PCT	Granted	2001245608	03/12/2001	2001245608	01/05/2007
LD140B-CA-PCT	Granted	2404212	03/12/2001	2404212	05/01/2012
LD140B-DE-EPT	Granted	01918544.6	03/12/2001	1265878	07/13/2011
LD140B-EP-EPT	Granted	01918544.6	03/12/2001	1265878	07/13/2011
LD140B-ES-EPT	Granted	01918544.6	03/12/2001	1265878	07/13/2011
LD140B-FR-EPT	Granted	01918544.6	03/12/2001	1265878	07/13/2011
LD140B-GB-EPT	Granted	01918544.6	03/12/2001	1265878	07/13/2011
LD140B-HK-FPR	Granted	03102703.1	04/14/2003	1050680	04/05/2012
LD140B-HU-PCT	Granted	P0300693	03/12/2001	229348	10/09/2013
LD140B-IL-PCT	Granted	151474	03/12/2001	151474	12/02/2009
LD140B-IN-MBA	Granted	2002/01074	03/12/2001	234024	04/29/2009
LD140B-IT-EPT	Granted	01918544.6	03/12/2001	1265878	07/13/2011
LD140B-JP-PCT	Granted	2001/568920	03/12/2001	4966468	04/06/2012
LD140B-KR-PCT	Granted	10-2002-7012290	03/12/2001	758069	09/05/2007
LD140B-MX-PCT	Granted	PA/A/02/009165	03/12/2001	240257	09/13/2006
LD140B-TW-NP	Granted	90105973	03/14/2001	1310383	06/01/2009
LD140C-US-CIP[1]	Reissue	09/775361	02/01/2001	6518421	02/11/2003
LD140C-US-REI	Granted	11/056606	02/11/2005	RE39356	10/17/2006

Docket Number	Title	Filing Number	Filing Date	Grant Date	Grant Number	Current Status
10103-EP-EPT	PROCESS AND FORMULATION CONTAINING EPOTHILONES AND ANALOGS THEREOF	04810277.6	04 Nov 2004			Abandoned
10103-US-NP	PROCESS AND FORMULATION CONTAINING EPOTHILONES AND ANALOGS THEREOF	10/979958	03 Nov 2004			Abandoned
10103-US-PSP[1]	PROCESS AND FORMULATION CONTAINING EPOTHILONES AND ANALOGS THEREOF	60/517020	04 Nov 2003			Expiry date
10103-WO-PCT	PROCESS AND FORMULATION CONTAINING EPOTHILONES AND ANALOGS THEREOF	PCT/US2004/036645	04 Nov 2004			Abandoned
10338-CA-PCT	BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO MICROTUBULE-STABILIZING AGENTS	2589482	30 Nov 2005			Abandoned
10338-EP-EPT	BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO	05858638.9	30 Nov 2005			Abandoned

Docket Number	Title	Filing Number	Filing Date	Grant Date	Grant Number	Current Status
	MICROTUBULE-STABILIZING AGENTS					
10338-JP-PCT	BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO MICROTUBULE-STABILIZING AGENTS	2007-544452	30 Nov 2005			Abandoned
10338-US-NP	BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO MICROTUBULE-STABILIZING AGENTS	11/289102	29 Nov 2005			Abandoned
10338-US-PSP[1]	BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO MICROTUBULE-STABILIZING AGENTS	60/631993	30 Nov 2004			Expiry date
10338-WO-PCT	BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO MICROTUBULE-STABILIZING AGENTS	PCT/US2005/043261	30 Nov 2005			Abandoned
LD0189-AR-NP	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	P020100286	25 Jan 2002			Abandoned
LD0189-AU-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	2002243548	16 Jan 2002			Abandoned
LD0189-BG-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	108019	16 Jan 2002			Abandoned
LD0189-BR-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	PI0206511-8	16 Jan 2002			Abandoned
LD0189-CA-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	2,434,566	16 Jan 2002			Abandoned
LD0189-CL-NP	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	2002-0155	25 Jan 2002			Abandoned
LD0189-CN-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	02804179.8	16 Jan 2002			Abandoned
LD0189-CO-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	03062.164	16 Jan 2002			Abandoned
LD0189-CZ-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	2003-2022	16 Jan 2002			Abandoned
LD0189-EE-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	0323/03PC	16 Jan 2002			Abandoned
LD0189-EG-MBA	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	83/2002	23 Jan 2002			Abandoned
LD0189-EP-EPT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	02709040.6	16 Jan 2002			Abandoned
LD0189-HR-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	P20030676A	16 Jan 2002			Abandoned
LD0189-HU-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	P0302567	16 Jan 2002			Abandoned
LD0189-ID-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	W-00200301436	16 Jan 2002			Abandoned
LD0189-IL-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	156580	16 Jan 2002			Abandoned
LD0189-IN-MBA	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	641/MUMNP/2003	16 Jan 2002			Abandoned
LD0189-IS-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	6890/2003	16 Jan 2002			Abandoned
LD0189-JP-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	PCT/US02/01102	16 Jan 2002			Abandoned
LD0189-	PARENTERAL FORMULATION FOR	10-2003-	16 Jan			Abandoned

Docket Number	Title	Filing Number	Filing Date	Grant Date	Grant Number	Current Status
KR-PCT	EPOTHILONE ANALOGS	7009824	2002			
LD0189-MX-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	PA/A2003/006485	16 Jan 2002			Abandoned
LD0189-MY-NP	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	PI20020258	23 Jan 2002			Abandoned
LD0189-NO-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	20033342	16 Jan 2002			Abandoned
LD0189-NZ-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	526869	16 Jan 2002			Abandoned
LD0189-PE-NP	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	000060/2002-OIN	25 Jan 2002			Abandoned
LD0189-PH-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	1-2003-500572	16 Jan 2002			Abandoned
LD0189-PK-MBA	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	0029/02	17 Jan 2002			Abandoned
LD0189-PL-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	PCT/US02/01102	16 Jan 2002			Abandoned
LD0189-RS-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	P583/03	16 Jan 2002			Abandoned
LD0189-RU-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	2003126171	16 Jan 2002			Abandoned
LD0189-SG-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	200303919-5	16 Jan 2002	31 Oct 2003	82368	Abandoned
LD0189-TH-NP	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	071381	25 Jan 2002			Abandoned
LD0189-TW-NP	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	91100785	18 Jan 2002			Abandoned
LD0189-US-CNT[1]	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	11/226017	14 Sep 2005			Abandoned
LD0189-US-CNT[3]	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	14/134172	19 Dec 2013			Abandoned
LD0189-US-PSP	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	60/264228	25 Jan 2001			Expiry date
LD0189-UY-NP	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	27.134	25 Jan 2002			Abandoned
LD0189-VE-NP	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	119-2002	24 Jan 2002			Abandoned
LD0189-WO-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	PCT/US02/01102	16 Jan 2002			Abandoned
LD0189-ZA-PCT	PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS	2003/5123	16 Jan 2002	29 Dec 2004	03/5123	Abandoned
LD0214-EG-MBA	POLYMORPHS OF AN EPOTHILONE ANALOG	864/2001	07 Aug 2001			Abandoned
LD0214-ID-PCT	POLYMORPHS OF AN EPOTHILONE ANALOG	W00200300248	01 Aug 2001	04 Mar 2009	035.260A	Abandoned
LD0214-MY-NP	POLYMORPHS OF AN EPOTHILONE ANALOG	PI20013545	26 Jul 2001	30 Nov 2007	MY-134129-A	Abandoned
LD0214-PE-NP	POLYMORPHS OF AN EPOTHILONE ANALOG	000818/2001-OIN	16 Aug 2001			Abandoned
LD0214-	POLYMORPHS OF AN EPOTHILONE	1-2001-	20 Jul	19 Oct	1-2001-	Abandoned

Docket Number	Title	Filing Number	Filing Date	Grant Date	Grant Number	Current Status
PH-NP	ANALOG	01863	2001	2007	01863	
LD0214-PK-MBA	POLYMORPHS OF AN EPOTHILONE ANALOG	702/2001	19 Jul 2001			Abandoned
LD0214-RS-PCT	POLYMORPHS OF AN EPOTHILONE ANALOG	P121/03	01 Aug 2001			Abandoned
LD0214-SG-PCT	POLYMORPHS OF AN EPOTHILONE ANALOG	200300203.7	01 Aug 2001	31 May 2005	91416	Abandoned
LD0214-UA-PCT	POLYMORPHS OF AN EPOTHILONE ANALOG	2003032259/A	01 Aug 2001	17 Apr 2006	75365	Abandoned
LD0214-US-PSP	POLYMORPHS OF AN EPOTHILONE ANALOG	60/225590	16 Aug 2000			Expiry date
LD0214-UY-NP	POLYMORPHS OF AN EPOTHILONE ANALOG	26.886	15 Aug 2001			Abandoned
LD0214-VN-PCT	POLYMORPHS OF AN EPOTHILONE ANALOG	1-2003-00147	01 Aug 2001	24 Jun 2008	7134	Abandoned
LD0214-WO-PCT	POLYMORPHS OF AN EPOTHILONE ANALOG	PCT/US2001/024540	01 Aug 2001			PCT CONVERT ED
LD0260-AU-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	2002247123	06 Feb 2002			Abandoned
LD0260-BG-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	108075	06 Feb 2002			Abandoned
LD0260-BR-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	PI0207487-7	06 Feb 2002			Abandoned
LD0260-CA-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	2438610	06 Feb 2002			Abandoned
LD0260-CN-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	02805251.X	06 Feb 2002			Abandoned
LD0260-CZ-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	2003-2541	06 Feb 2002			Abandoned
LD0260-EE-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	P200300396	06 Feb 2002			Abandoned
LD0260-EP-EPT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	02714885.7	06 Feb 2002			Abandoned
LD0260-HK-FPR	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	04103173.9	05 May 2004			Abandoned
LD0260-HR-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	P20030756A	06 Feb 2002			Abandoned
LD0260-HU-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	P0303175	06 Feb 2002			Abandoned
LD0260-ID-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	W-00200301611	06 Feb 2002			Abandoned
LD0260-IL-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	156988	06 Feb 2002			Abandoned
LD0260-IN-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	PCT/US02/04255	06 Feb 2002			Abandoned
LD0260-IS-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	6918/2003	06 Feb 2002			Abandoned
LD0260-JP-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	2002-565596	06 Feb 2002			Abandoned
LD0260-KR-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	10-2003-7010871	06 Feb 2002			Abandoned

Docket Number	Title	Filing Number	Filing Date	Grant Date	Grant Number	Current Status
LD0260-MX-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	PA/A2003/007394	06 Feb 2002			Abandoned
LD0260-MY-NP	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	PI20020547	19 Feb 2002			Abandoned
LD0260-NO-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	20033684	06 Feb 2002			Abandoned
LD0260-PH-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	1-2003-500634	06 Feb 2002			Abandoned
LD0260-PL-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	P-363362	06 Feb 2002			Abandoned
LD0260-RS-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	P652/2003	06 Feb 2002			Abandoned
LD0260-RU-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	2003128311	06 Feb 2002			Abandoned
LD0260-SG-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	200305154-7	06 Feb 2002			Abandoned
LD0260-SK-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	PCT/US02/04255	06 Feb 2002			Abandoned
LD0260-TH-NP	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	071814	18 Feb 2002			Abandoned
LD0260-TW-NP	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	91102675	18 Feb 2002			Abandoned
LD0260-US-PSP	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	60/269836	20 Feb 2001			Expiry date
LD0260-WO-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	PCT/US02/04255	06 Feb 2002			Abandoned
LD0260-ZA-PCT	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES	2003/6173	06 Feb 2002	23 Feb 2005	03/6173	Abandoned
LD0268-CA-PCT	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	2440555	05 Mar 2002			Abandoned
LD0268-CN-PCT	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	02806571.9	05 Mar 2002			Abandoned
LD0268-HK-FPR[2]	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS.					Abandoned
LD0268-ID-PCT	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	W00200301786	05 Mar 2002			Abandoned
LD0268-IL-PCD	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES					Not Filed
LD0268-IN-PCT	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	01335/DEL/2003	05 Mar 2002			Abandoned

Docket Number	Title	Filing Number	Filing Date	Grant Date	Grant Number	Current Status
LD0268-JP-PCT	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	2002-571044	05 Mar 2002			Abandoned
LD0268-KR-PCT	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	10-2003-7011867	05 Mar 2002			Abandoned
LD0268-MY-NP	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	PI20020846	08 Mar 2002			Abandoned
LD0268-PH-PCT	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	1-2003-500768	05 Mar 2002			Abandoned
LD0268-PL-PCT	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	P-368973	05 Mar 2002			Abandoned
LD0268-RS-PCT	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	P-716/03	05 Mar 2002			Abandoned
LD0268-US-CNT	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	12/906511	18 Oct 2010			Abandoned
LD0268-US-DIV[2]	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	11/009579	10 Dec 2004			Abandoned
LD0268-US-PSP	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	60/316395	31 Aug 2001			Expiry date
LD267-US-PCP	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	60/275,801	14 Mar 2001			
LD0268-WO-PCT	COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	PCT/US2002/006746	05 Mar 2002			PCT CONVERTED
LD272-US-PSP	METHODS OF ADMINISTERING EPOTHILONE ANALOGS FOR THE TREATMENT OF CANCER	60/290019	11 May 2001			
LD272-WO-PCT[1]	PHARMACEUTICAL FORMS OF EPOTHILONES FOR ORAL ADMINISTRATION	PCT/US02/01693	22 Jan 2002			
LD272-WO-PCT	PHARMACEUTICAL FORMS OF EPOTHILONES FOR ORAL	PCT/US02/02518	22 Jan 2002			

Docket Number	Title	Filing Number	Filing Date	Grant Date	Grant Number	Current Status
	ADMINISTRATION					
LD0283-EP-EPT	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	03759335.7	22 Sep 2003			Abandoned
LD0283-GE-PCT	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	8758	22 Sep 2003			Abandoned
LD0283-HK-FPR	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	05105683.6	06 Jul 2005			Abandoned
LD0283-HR-PCT	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	P20050278A	22 Sep 2003			Abandoned
LD0283-ID-PCT	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	W002005007 02	22 Sep 2003			Abandoned
LD0283-IN-PCT	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	PCT/US03/2 9628	22 Sep 2003			Not Filed
LD0283-IS-PCT	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	7768	22 Sep 2003			Abandoned
LD0283-KR-PCT	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	10-2005-7004892	22 Sep 2003			Abandoned
LD0283-NZ-PCT	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	538310	22 Sep 2003			Abandoned
LD0283-PH-PCT	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	1-2005-500426	22 Sep 2003			Abandoned
LD0283-PL-PCT	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	P-375902	22 Sep 2003			Abandoned
LD0283-RS-PCT	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	P20050235	22 Sep 2003			Abandoned
LD0283-SG-PCT	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL	200501334.7	22 Sep 2003	31 Jan 2007	110738	Abandoned

Docket Number	Title	Filing Number	Filing Date	Grant Date	Grant Number	Current Status
	STRUCTURES OF EPOTHILONE B					
LD0283-UA-PCT	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	200503843	22 Sep 2003			Abandoned
LD0283-US-PSP	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	60/412994	23 Sep 2002			Expiry date
LD0283-US-REI[2]	IMPROVED METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	12/537287	07 Aug 2009			Abandoned
LD0283-VN-PCT	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	1-2005-00393	22 Sep 2003			Abandoned
LD0283-WO-PCT	METHODS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILONE B, AND X-RAY CRYSTAL STRUCTURES OF EPOTHILONE B	PCT/US2003/029628	22 Sep 2003			PCT CONVERTED
LD0284-ID-PCT	METHODS OF ADMINISTERING EPOTHILONE ANALOGS FOR THE TREATMENT OF CANCER	W00200301612	22 Jan 2002			Abandoned
LD0284-MY-NP	METHODS OF ADMINISTERING EPOTHILONE ANALOGS FOR THE TREATMENT OF CANCER	PI20020269	24 Jan 2002			Abandoned
LD0284-PH-PCT	METHODS OF ADMINISTERING EPOTHILONE ANALOGS FOR THE TREATMENT OF CANCER	1-2003-500574	22 Jan 2002	19 Oct 2007	1-2003-500574	Abandoned
LD0284-PK-MBA	METHODS OF ADMINISTERING EPOTHILONE ANALOGS FOR THE TREATMENT OF CANCER	0050/02	23 Jan 2002			Abandoned
LD0284-US-PSP	METHODS OF ADMINISTERING EPOTHILONE ANALOGS FOR THE TREATMENT OF CANCER	60/290008	11 May 2001			Expiry date
LD0284-WO-PCT	METHODS OF ADMINISTERING EPOTHILONE ANALOGS FOR THE TREATMENT OF CANCER	PCT/US2002/001813	22 Jan 2002			PCT CONVERTED
LD125-AT-EPD	EPOTHILONE DERIVATIVES	04021059.3	03 Sep 2004	25 Mar 2009	1493738	Not Filed
LD125-BE-EPD	EPOTHILONE DERIVATIVES	04021059.3	03 Sep 2004	25 Mar 2009	1493738	Not Filed
LD125-CH-EPD	EPOTHILONE DERIVATIVES	04021059.3	03 Sep 2004	25 Mar 2009	1493738	Not Filed
LD125-DK-EPD	EPOTHILONE DERIVATIVES	04021059.3	03 Sep 2004	25 Mar 2009	1493738	Not Filed
LD125-EP-EPD[2]	EPOTHILONE DERIVATIVES	04028581.9	16 Jun 1998			Abandoned
LD125-	EPOTHILONE DERIVATIVES	04028580.1	16 Jun			Abandoned

Docket Number	Title	Filing Number	Filing Date	Grant Date	Grant Number	Current Status
EP-EPD[3]			1998			
LD125-FI-EPD	EPOTHILONE DERIVATIVES	04021059.3	03 Sep 2004	25 Mar 2009	1493738	Not Filed
LD125-GR-EPD	EPOTHILONE DERIVATIVES	04021059.3	03 Sep 2004	25 Mar 2009	1493738	Not Filed
LD125-ID-PCT	EPOTHILONE DERIVATIVES	W-20000002	16 Jun 1998	01 Nov 2004	ID0014513	Abandoned
LD125-IE-EPD	EPOTHILONE DERIVATIVES	04021059.3	03 Sep 2004	25 Mar 2009	1493738	Not Filed
LD125-LU-EPD	EPOTHILONE DERIVATIVES	04021059.3	03 Sep 2004	25 Mar 2009	1493738	Not Filed
LD125-MC-EPD	EPOTHILONE DERIVATIVES	04021059.3	03 Sep 2004	25 Mar 2009	1493738	Not Filed
LD125-MY-NP	EPOTHILONE DERIVATIVES	PI98003121	06 Jul 1998	30 Jun 2006	MY-124151-A	Abandoned
LD125-PE-NP	EPOTHILONE DERIVATIVES	0604/98	08 Jul 1998			Abandoned
LD125-PK-MBA	EPOTHILONE DERIVATIVES	0705/98	07 Jun 1998			Abandoned
LD125-UA-PCT	EPOTHILONE DERIVATIVES	2000020654/A	16 Jun 1998	16 Feb 2004	63962	Abandoned
LD125-WO-PCT	EPOTHILONE DERIVATIVES	PCT/US98/12550	16 Jun 1998			PCT CONVERTED
LD125A#-US-PSP[1]	EPOTHILONE DERIVATIVES	60/067524	04 Dec 1997			Expiry date
	EPOTHILONE DERIVATIVES	60/051951	08 July 1997			
LD125B-US-EXT	EPOTHILONE DERIVATIVES					Filing decision
LD125B-US-NP	EPOTHILONE DERIVATIVES	09/084542	26 May 1998	12 Aug 2003	6605599	CLOSED/INACTIVE
LD140-AR-NP	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	P980106174	04 Dec 1998			Abandoned
LD140-AT-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-AU-PCT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	16134/99	30 Nov 1998			Abandoned
LD140-BE-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-CA-PCT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR	2312098	30 Nov 1998	30 Dec 2008	2312098	Abandoned

Docket Number	Title	Filing Number	Filing Date	Grant Date	Grant Number	Current Status
	THE PREPARATION OF EPOTHILONE					
LD140-CH-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-CL-NP	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	1998-2828	23 Nov 1998			Abandoned
LD140-CO-NP	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	98071.207	01 Dec 1998			Abandoned
LD140-CY-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-DE-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-DK-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-EC-NP	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	SP-98-2762	30 Nov 1998			Abandoned
LD140-EG-NP	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	1504/98	03 Dec 1998			Abandoned
LD140-EP-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	98960564.7	30 Nov 1998			Abandoned
LD140-ES-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-FI-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-FR-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-GB-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR	PCT/US98/25408	30 Nov 1998			Abandoned

Docket Number	Title	Filing Number	Filing Date	Grant Date	Grant Number	Current Status
	THE PREPARATION OF EPOTHILONE					
LD140-GR-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-IE-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-IT-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-JP-PCT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	2000-522878	30 Nov 1998			Abandoned
LD140-LU-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-MC-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-MY-NP	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PI9805296	21 Nov 1998			Abandoned
LD140-NL-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-PE-NP	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	001181/98	04 Dec 1998			Abandoned
LD140-PH-NP	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	1-1998-03004	10 Nov 1998			Abandoned
LD140-PK-NP	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	1177/98	18 Nov 1998			Abandoned
LD140-PT-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-SE-EPT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR	PCT/US98/25408	30 Nov 1998			Abandoned

Docket Number	Title	Filing Number	Filing Date	Grant Date	Grant Number	Current Status
	THE PREPARATION OF EPOTHILONE					
LD140-TH-NP	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE					Abandoned
LD140-TW-NP	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	87119882	01 Dec 1998			Abandoned
LD140-UY-NP	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE					Abandoned
LD140-VE-NP	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	2727-98	03 Dec 1998			Abandoned
LD140-WO-PCT	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	PCT/US98/25408	30 Nov 1998			Abandoned
LD140-ZA-NP	A PROCESS FOR THE PREPARATION OF RING-OPENED EPOTHILONE INTERMEDIATES WHICH ARE USEFUL FOR THE PREPARATION OF EPOTHILONE	98/10993	01 Dec 1998	30 Aug 2000	98/10993	Abandoned
LD140B-AR-NP	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	P010101306	20 Mar 2001			Abandoned
LD140B-CL-NP	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	2001-575	14 Mar 2001			Abandoned
LD140B-EC-NP	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	2001-3971	16 Mar 2001			Abandoned
LD140B-EG-MBA	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	237/2001	12 Mar 2001			Abandoned
LD140B-EP-EPD	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	07020071.2	12 Oct 2007			Abandoned
LD140B-MY-NP	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	PI20011219	15 Mar 2001			Abandoned
LD140B-PE-NP	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	0256/01	20 Mar 2001			Abandoned
LD140B-PH-NP	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	1-2001-00451	27 Feb 2001			Abandoned
LD140B-PK-MBA	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	198/2001	09 Mar 2001			Abandoned
LD140B-SG-PCT	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	200205520.0	12 Mar 2001	30 Nov 2004	91644	Abandoned
LD140B-TH-NP	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	064290	16 Mar 2001			Abandoned
LD140B-US-CIP[1]	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	09/528526	20 Mar 2000			Abandoned
LD140B-UY-NP	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	26.624	19 Mar 2001			Abandoned
LD140B-	A PROCESS FOR THE PREPARATION OF	576/2001	16 Mar			Abandoned

Docket Number	Title	Filing Number	Filing Date	Grant Date	Grant Number	Current Status
VE-NP	EPOTHILONE ANALOGS		2001			
LD140B-WO-PCT	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	PCT/US2001/007749	12 Mar 2001			PCT CONVERT ED
LD140C-EP-EPT	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	02705896.5	22 Jan 2002			Abandoned
LD140C-TW-NP	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	91101556	30 Jan 2002			Abandoned
LD140C-WO-PCT	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	PCT/US02/01853	22 Jan 2002			Abandoned
LD140D-US-CIP[1]	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	09/946721	05 Sep 2001			Abandoned
	A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS	60/067550	04 Dec 1997			

APOSTILLE

(CONVENTION DE LA HAYE DU 5 OCTOBRE 1961)

1. COUNTRY: UNITED STATES OF AMERICA
2. THIS PUBLIC DOCUMENT HAS BEEN SIGNED BY:
ASHLEY HAMILTON
3. ACTING IN THE CAPACITY OF:
NOTARY PUBLIC OF NEW JERSEY
4. BEARS THE SEAL/STAMP OF:
ASHLEY HAMILTON, NOTARY

CERTIFIED

5. AT TRENTON, NEW JERSEY
6. THE 3RD DAY OF OCTOBER 2019
7. BY: Elizabeth Maher Muoio
State Treasurer
8. NO: A699521
9. SEAL/STAMP:
10. SIGNATURE



A handwritten signature in black ink, appearing to read "Elizabeth Maher Muoio".

Elizabeth Maher Muoio
State Treasurer

Certificate Number: 1417643810

Verify this certificate at

https://www1.state.nj.us/TYTR_StandingCert/JSP/Verify_Cert.jsp

Poder de Abogado	Power of Attorney
Yo, R-Pharm US Operating, LLC domiciliado en 3120 Princeton Pike, Suite 301 Lawrence New Jersey 08648, Estados Unidos de América,	I, R-Pharm US Operating, LLC domiciled at 3120 Princeton Pike, Suite 301 Lawrence New Jersey 08648, United States of America,
por el presente otorgo a	hereby grant to
ANDREA TOBOS MATEUS , tpa 148.648, domiciliado en la Calle 151 No. 18 A – 34 Oficina 409 Bogotá D.C., Colombia, poder amplio y suficiente para obtener la protección de mi propiedad industrial y contra la competencia desleal, a cuyo efecto autorizo a dicho apoderado para que me represente ante cualquier entidad o personas, ejerzan o no jurisdicción, especialmente ante las del orden administrativo, contencioso- administrativo y judicial, así como los tribunales de arbitramento, en todo lo concerniente a los siguientes asuntos:	ANDREA TOBOS MATEUS , tpa 148.648, domiciled at Calle 151 No. 18 A – 34 Oficina 409 Bogotá D.C., Colombia, full and sufficient power so that she may obtain the protection of my industrial property and against the unfair competition, for which purpose I authorize said attorney to represent me before any authorities or persons, with or without jurisdiction, especially those administrative, administrative contentious and judicial, as well as before Arbitration Court, in all matters concerning the following:
a) Obtención de patentes de invención, patentes de modelos de utilidad, registro de diseños industriales, esquemas de trazado de circuitos integrados, registro de marcas, marcas colectivas, marcas defensivas, marcas de servicio, lemas comerciales, nombres comerciales, enseñas, nombres de dominio y variedades vegetales; inscripción de fusiones, cambios de nombre, traspasos, cambios de domicilio y de dirección; inscripción de contratos de prenda, inscripción de licencias de uso, embargos, renovaciones y otros actos que afecten o limiten los mencionados derechos de propiedad industrial; presentación y tramitación de oposiciones, acciones de cancelación, acciones de nulidad, acciones de nulidad y restablecimiento del derecho, medidas cautelares, acciones por infracción de derechos, y demás acciones judiciales, relacionadas con procesos de propiedad industrial, competencia desleal y protección del consumidor,	a) Obtainment of patents of invention, patents for utility models and industrial designs registrations, integrated circuits layout-designs registrations, registration of trademarks, collective, defensive and service marks, slogans, commercial names, trade emblems, domain names and vegetal varieties; recordal of mergers, changes of name, assignments, changes of domicile and address; security interests; recordal of license of use agreements, liens, renewals and other acts that affect or limit the mentioned industrial property rights; filing and prosecution of oppositions, cancellation actions, annulment actions, annulment and reinstatement of right action, precautionary injunctions, infringement actions, and all administrative and judicial actions available for the prosecution of proceedings related to industrial property matters, unfair competition and protection of consumers,
a cuyo efecto la faculta para presentar solicitudes, peticiones y demandas, interponer recursos, reclamos, pagar impuestos y tasas, recibir, transigir y desistir, incluyendo facultades para entrar en acuerdos amigables, conciliaciones y transacciones, abandonar solicitudes y renunciar a derechos de propiedad industrial, y en general, a dar ante las autoridades competentes todos los pasos necesarios para la debida protección de mi propiedad industrial. Asimismo, se concede a la mencionada mandataria poder suficiente para recibir notificaciones a mi nombre, otorgar poderes a quienes vayan a representarme judicial y extrajudicialmente, responder en juicio a todas las reclamaciones o demandas que por motivo de los derechos de propiedad industrial se presentaren y hacer cuanto fuere necesario ante las autoridades administrativas o judiciales de cualquier orden para el cumplimiento de este mandato, dándoles igualmente facultad para sustituir el presente poder y en caso necesario, revocar dichas sustituciones.	to which end it empowers she to file requests, petitions and lawsuits, appeals and objections, pay taxes, receive, including faculties to enter into settlement agreements, conciliations and transactions, abandon applications and abandon intellectual property rights and, in general, to take all the actions with the competent authorities in order to duly protect my intellectual property. In addition, sufficient power is granted to said mandatory to receive notifications for and on my behalf, to confer powers on those who are to represent me judicially and extrajudicially, to answer in court in the matter of all claims and demands that may be presented in connection with the intellectual property rights, and to do everything that may be required with administrative or judicial officers of any class to comply this power, giving them likewise faculty to substitute these presents and revoke such substitutions if necessary.

Hoy 26 de September de 2019,
compareció(eron) ante mi
Demetrios Kydonieus
quien(es) conozco personalmente y que firma(n) este
documento en representación de la compañía denominada:
R-Pharm US Operating, LLC

Certifico:

1. Que he visto los siguientes documentos:

- 2019 New Jersey State License
- Delaware Certificate of Good Standing

2. Que dichos documentos prueban lo siguiente:

2.1. Que **R-Pharm US Operating, LLC**
es una Compañía legalmente constituida y existente de
acuerdo con las leyes de Delaware Estados Unidos de
América.

2.2. Que el domicilio de dicha Compañía es
3120 Princeton Pike, Suite 301 Lawrence New Jersey 08648,
Estados Unidos de América

2.3. Que el objeto u objetos para los cuales se otorga el
presente poder están comprendidos dentro del objeto
social de la mencionada Compañía.

2.4. Que el(los) Sr.(Sres.)
Demetrios Kydonieus
está(n) autorizado(s) para otorgar el presente Poder.

Ciudad Lawrenceville

Estado NS

Hoy 26 September de 2019

On this 26 day of September 2019
appeared before me
Demetrios Kydonieus
who(m) I know personally and who(m) signed this
document as representative(s) of the Company named:

R-Pharm US Operating, LLC

I certify:

1. That I have seen the following documents:

- 2019 New Jersey State License
- Delaware Certificate of Good Standing

2. That the above documents duly prove the
following:

2.1. That **R-Pharm US Operating, LLC**
is a Company legally constituted and in existence in
accordance with the laws of Delaware United States
of America.

2.2. That the domicile of said Company is
3120 Princeton Pike, Suite 301 Lawrence New Jersey 08648,
United States of America

2.3. That the purpose or purposes for which the present
Power of Attorney is granted are comprised within the
corporation purposes set forth in the charter of the
mentioned Company.

2.4. That Mr.(Messrs.)
Demetrios Kydonieus
is(are) authorized to grant the present Power of Attorney.

City Lawrenceville

State NS

This 26 day of September 2019

This document does need to be legalized by Apostille.

ASHLEY HAMILTON
Notary Public - State of New Jersey
My Commission Expires Mar 9, 2023

Ashley Hamilton

Dado y firmado hoy <u>September 26</u> 2019 en <u>Lawrenceville, NJ</u> por <u>Demetrios Kydonieus</u> Firma <u></u>	Given and signed this <u>September 26</u>, 2019 in <u>Lawrenceville, NJ</u> by <u>Demetrios Kydonieus</u> Signature <u></u>
---	---

APOSTILLA**(Convención de La Haya del 5 de octubre de 1961)**

1. País: Estados Unidos de América
2. Este documento público ha sido firmado por: ASHLEY HAMILTON
3. actuando en calidad de NOTARIO PÚBLICO DE NUEVA JERSEY
4. está marcado con la estampilla/sello del ASHLEY HAMILTON, NOTARIO

CERTIFICADO

5. en Trenton, Nueva Jersey
6. el 3 de octubre de 2019
7. por Elizabeth Maher Muoio
Tesorero Estatal
8. No. A699521
9. Sellado, El Gran Sello del Estado de Nueva Jersey
10. Firmado por Elizabeth Maher Muoio, Tesorero Estatal

Número de certificado: 1417643810

Verifique este certificado en <https://www1.state.nj.us/TYTR StandingCert/ISP/Verify Cert.jsp>

ESTA ES UNA TRADUCCIÓN FIEL Y VERAZ AL IDIOMA ESPAÑOL DE UN DOCUMENTO ESCRITO EN IDIOMA INGLÉS REALIZADA EL 29 DE OCTUBRE DE 2019.

MARIA CRISTINA HOLGUIN
TRADUCTOR E INTÉRPRETE OFICIAL
CERTIFICADO DE IDONEIDAD PROFESIONAL No. 0274
UNIVERSIDAD NACIONAL – Febrero de 2009
Cédula No. 52.862.623 de Bogotá

ueto yuu
MARIA CRISTINA HOLGUIN
TRADUCCIONES
TRADUCTORA OFICIAL
Certificado de idoneidad N 0274 de 2009



NOTARÍA 22 DEL CÍRCULO DE
BOGOTÁ D.C.
DILIGENCIA DE AUTENTICACIÓN
FIRMA REGISTRADA

NOTARÍA
VEINTIDOS
509/33460a5d

El Suscrito Notario Veintidos del Círculo de Bogotá D.C.
CERTIFICA Que la Firma que aparece en el presente
documento coincide con la Registrada en esta Notaría por:

HOLGUIN BORRERO MARIA CRISTINA
con C.C. 52862623

según confrontación que le ha hecho de ella.

Bogotá D.C. 2019-10-29 10:21:04

MANUEL J. CAROPRESE MENDEZ
NOTARIO 22 DEL CÍRCULO DE BOGOTÁ D.C.


www.notariaenlinea.com
Cod. Verificación: 4y9k6

A INSISTENCIA DEL
INTERESADO



Manuel J. Caroprese Mendez

[La anterior Apostilla acompaña un Poder de Abogado otorgado por R-Pharm US Operating, LLC a Andrea Tobos Mateus, a doble columna en idiomas inglés y español, firmado por Demetrios Kydomeus.

Igualmente acompaña una certificación notarial firmada por Ashley Hamilton, Notario Público - Estado de Nueva Jersey. Su comisión vence el 9 de marzo de 2023]

Handwritten signature

ESTA ES UNA TRADUCCIÓN FIEL Y VERAZ AL IDIOMA ESPAÑOL DE UN DOCUMENTO ESCRITO EN IDIOMA INGLES REALIZADA EL 29 DE OCTUBRE DE 2019.

MARIA CRISTINA HOLGUIN
TRADUCTOR E INTÉRPRETE OFICIAL
CERTIFICADO DE IDONEIDAD PROFESIONAL No. 0274
UNIVERSIDAD NACIONAL - Febrero de 2009
Cédula No. 52.862.623 de Bogotá

Handwritten signature
MARIA CRISTINA HOLGUIN
TRADUCCIONES
TRADUCTORA OFICIAL
Certificado de Idoneidad N. 0274 de 2009



**NOTARÍA 22 DEL CÍRCULO DE
BOGOTÁ D.C.
DILIGENCIA DE AUTENTICACIÓN
FIRMA REGISTRADA**

22
NOTARIA
VEINTIDOS

509-2258cf59

El Suscrito Notario Veintidos del Círculo de Bogotá D.C.
CERTIFICA Que la Firma que aparece en el presente
documento coincide con la Registrada en esta Notaría por:

HOLGUIN BORRERO MARIA CRISTINA
con C.C. 52862623

según confrontación que le ha hecho de ella.

Bogotá D.C. 2019-10-29 10:21:05



MANUEL J. CAROPRESE MENDEZ
NOTARIO 22 DEL CÍRCULO DE BOGOTÁ D.C.

www.notariaenlinea.com
Cod-Verificación-4y0kq

A INSISTENCIA DEL
INTERESADO



Manuel J. Caroprese Mendez

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800.176.089-2

- / -



RECIBO DE CAJA

No. 19 - 0095812

07 de Noviembre de 2019 - 13:39:54

RECIBIDO DE : TOBOS ABOGADOS SAS

NI 900.367.556

*** Soporte del Pago ***

TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	VR. PAGO
CONSIGNACION	BANCO DE BOGOTA	062754387	974028160	07/11/2019	\$404.500,00

*** Conceptos Pagados ***

CANT	RENTISTICO	CONCEPTO	VR. UNITARIO	VR. CONCEPTO
1	50005-01-01 SOLICITUDES	1642 S.DISTINTIVO CAMBIOO TITULARIDAD-TRANSFERENCIA INSCRIPCION	\$404.500,00	\$404.500,00
				\$404.500,00

SON: *** CUATROCIENTOS CUATRO MIL QUINIENTOS PESOS MONEDA CORRIENTE ***

Responsable: _____

Superintendencia de Industria y Comercio
Radicado: 03011545
Dependencia: 2020 Fecha: 2019-11-07 15:43:16
Tipo aplicación: Complemento de Información
Folios : 39